Abstract
The analysis of positron emission tomography (PET) scan image is challenging due to a high level of noise and a low resolution and also because differences between healthy and demented are very subtle. High dimensional classification methods based on PET have been proposed to automatically discriminate between normal control group (NC) patients and patients with Alzheimer’s disease (AD), with mild cognitive impairment (MCI), and mild cognitive impairment converting to Alzheimer’s disease (MCIAD ) (a group of patients that clearly degrades to AD). We developed a voxelbased method for volumetric image analysis. We performed 3 classification experiments AD vs CG, AD vs MCI, MCIAD vs MCI. We will also give a small demonstration of the presented method on a set of face images. This method is capable to extract information about the location of metabolic changes induced by Alzheimer’s disease that directly relies statistical features and brain regions of interest (ROIs). We produce “maps” to visualize the most informative regions of the brain and compare them with voxel-wise statistics. Using the mean intensity of about 2000 6 × 6 × 6mm patches, selected by the extracted map, as input for a classifier we obtain a classification rate of 95.5%.
Keywords: AD, Alzheimer’s disease, classification, Computer-aided diagnosis, machine learning, MCI, PET scan, random forest.
Current Alzheimer Research
Title:Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization
Volume: 13 Issue: 5
Author(s): V. Vigneron, A. Kodewitz, A. M. Tome, S. Lelandais and E. Lang
Affiliation:
Keywords: AD, Alzheimer’s disease, classification, Computer-aided diagnosis, machine learning, MCI, PET scan, random forest.
Abstract: The analysis of positron emission tomography (PET) scan image is challenging due to a high level of noise and a low resolution and also because differences between healthy and demented are very subtle. High dimensional classification methods based on PET have been proposed to automatically discriminate between normal control group (NC) patients and patients with Alzheimer’s disease (AD), with mild cognitive impairment (MCI), and mild cognitive impairment converting to Alzheimer’s disease (MCIAD ) (a group of patients that clearly degrades to AD). We developed a voxelbased method for volumetric image analysis. We performed 3 classification experiments AD vs CG, AD vs MCI, MCIAD vs MCI. We will also give a small demonstration of the presented method on a set of face images. This method is capable to extract information about the location of metabolic changes induced by Alzheimer’s disease that directly relies statistical features and brain regions of interest (ROIs). We produce “maps” to visualize the most informative regions of the brain and compare them with voxel-wise statistics. Using the mean intensity of about 2000 6 × 6 × 6mm patches, selected by the extracted map, as input for a classifier we obtain a classification rate of 95.5%.
Export Options
About this article
Cite this article as:
Vigneron V., Kodewitz A., Tome M. A., Lelandais S. and Lang E., Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666160314144822
DOI https://dx.doi.org/10.2174/1567205013666160314144822 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies
Current Alzheimer Research Effect of S-equol and Soy Isoflavones on Heart and Brain
Current Cardiology Reviews An Historical Perspective on Efforts to Treat Transmissible Spongiform Encephalopathy
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Current Pharmaceutical Design Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Auditory and Visual Mismatch Negativity in Psychiatric Disorders: A Review
Current Psychiatry Reviews Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews Relation of Obesity to Cognitive Function: Importance of Central Obesity and Synergistic Influence of Concomitant Hypertension. The Framingham Heart Study
Current Alzheimer Research Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway
CNS & Neurological Disorders - Drug Targets Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Targeting the PAC1 Receptor for Neurological and Metabolic Disorders
Current Topics in Medicinal Chemistry Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry